#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=The present study confirms that a remarkable number of patients with ACC who are operated on with radical intent are destined to relapse .
2-1	14-17	The	abstract[2]	new[2]	coref	7-2[23_2]
2-2	18-25	present	abstract[2]	new[2]	_	_
2-3	26-31	study	abstract[2]	new[2]	_	_
2-4	32-40	confirms	_	_	_	_
2-5	41-45	that	_	_	_	_
2-6	46-47	a	person[3]	new[3]	_	_
2-7	48-58	remarkable	person[3]	new[3]	_	_
2-8	59-65	number	person[3]	new[3]	_	_
2-9	66-68	of	person[3]	new[3]	_	_
2-10	69-77	patients	person[3]|person[4]	new[3]|new[4]	coref	10-8[51_4]
2-11	78-82	with	person[3]|person[4]	new[3]|new[4]	_	_
2-12	83-86	ACC	person[3]|person[4]|organization	new[3]|new[4]|new	coref	3-1
2-13	87-90	who	person[3]|person[4]	new[3]|new[4]	_	_
2-14	91-94	are	person[3]|person[4]	new[3]|new[4]	_	_
2-15	95-103	operated	person[3]|person[4]	new[3]|new[4]	_	_
2-16	104-106	on	person[3]|person[4]	new[3]|new[4]	_	_
2-17	107-111	with	person[3]|person[4]	new[3]|new[4]	_	_
2-18	112-119	radical	person[3]|person[4]|abstract[6]	new[3]|new[4]|new[6]	_	_
2-19	120-126	intent	person[3]|person[4]|abstract[6]	new[3]|new[4]|new[6]	_	_
2-20	127-130	are	_	_	_	_
2-21	131-139	destined	_	_	_	_
2-22	140-142	to	_	_	_	_
2-23	143-150	relapse	_	_	_	_
2-24	151-152	.	_	_	_	_

#Text=ACC
3-1	153-156	ACC	organization	giv	coref	14-12

#Text=recurrence portends a worse prognosis and has a huge impact on quality of life ;
4-1	157-167	recurrence	event	new	coref	14-12[83_0]
4-2	168-176	portends	_	_	_	_
4-3	177-178	a	abstract[9]	new[9]	_	_
4-4	179-184	worse	abstract[9]	new[9]	_	_
4-5	185-194	prognosis	abstract[9]	new[9]	_	_
4-6	195-198	and	_	_	_	_
4-7	199-202	has	_	_	_	_
4-8	203-204	a	abstract[10]	new[10]	coref	17-11[109_10]
4-9	205-209	huge	abstract[10]	new[10]	_	_
4-10	210-216	impact	abstract[10]	new[10]	_	_
4-11	217-219	on	abstract[10]	new[10]	_	_
4-12	220-227	quality	abstract[10]|abstract[11]	new[10]|new[11]	_	_
4-13	228-230	of	abstract[10]|abstract[11]	new[10]|new[11]	_	_
4-14	231-235	life	abstract[10]|abstract[11]|abstract	new[10]|new[11]|new	_	_
4-15	236-237	;	_	_	_	_

#Text=therefore , investigators have considered the use of adjuvant mitotane therapy following surgical operation .
5-1	238-247	therefore	_	_	_	_
5-2	248-249	,	_	_	_	_
5-3	250-263	investigators	person	new	_	_
5-4	264-268	have	_	_	_	_
5-5	269-279	considered	_	_	_	_
5-6	280-283	the	event[14]	new[14]	_	_
5-7	284-287	use	event[14]	new[14]	_	_
5-8	288-290	of	event[14]	new[14]	_	_
5-9	291-299	adjuvant	event[14]|abstract[16]	new[14]|new[16]	coref	10-24[56_16]
5-10	300-308	mitotane	event[14]|abstract|abstract[16]	new[14]|new|new[16]	coref	6-14[22_0]
5-11	309-316	therapy	event[14]|abstract[16]	new[14]|new[16]	_	_
5-12	317-326	following	event[14]	new[14]	_	_
5-13	327-335	surgical	event[14]|event[17]	new[14]|new[17]	_	_
5-14	336-345	operation	event[14]|event[17]	new[14]|new[17]	_	_
5-15	346-347	.	_	_	_	_

#Text=However , a limited number of often small-sized studies reporting the outcome of adjuvant mitotane is available .
6-1	348-355	However	_	_	_	_
6-2	356-357	,	_	_	_	_
6-3	358-359	a	abstract[18]	new[18]	_	_
6-4	360-367	limited	abstract[18]	new[18]	_	_
6-5	368-374	number	abstract[18]	new[18]	_	_
6-6	375-377	of	abstract[18]	new[18]	_	_
6-7	378-383	often	abstract[18]|abstract[19]	new[18]|new[19]	coref	8-1[32_19]
6-8	384-395	small-sized	abstract[18]|abstract[19]	new[18]|new[19]	_	_
6-9	396-403	studies	abstract[18]|abstract[19]	new[18]|new[19]	_	_
6-10	404-413	reporting	abstract[18]|abstract[19]	new[18]|new[19]	_	_
6-11	414-417	the	abstract[18]|abstract[19]|abstract[20]	new[18]|new[19]|new[20]	coref	7-15[28_20]
6-12	418-425	outcome	abstract[18]|abstract[19]|abstract[20]	new[18]|new[19]|new[20]	_	_
6-13	426-428	of	abstract[18]|abstract[19]|abstract[20]	new[18]|new[19]|new[20]	_	_
6-14	429-437	adjuvant	abstract[18]|abstract[19]|abstract[20]|person|abstract[22]	new[18]|new[19]|new[20]|new|giv[22]	coref|coref	7-12[0_22]|15-18
6-15	438-446	mitotane	abstract[18]|abstract[19]|abstract[20]|abstract[22]	new[18]|new[19]|new[20]|giv[22]	_	_
6-16	447-449	is	_	_	_	_
6-17	450-459	available	_	_	_	_
6-18	460-461	.	_	_	_	_

#Text=In the present study , we explored the relationship between target mitotane concentrations and patient outcome using the TTR , analogous to warfarin treatment .
7-1	462-464	In	_	_	_	_
7-2	465-468	the	abstract[23]	giv[23]	coref	13-2[66_23]
7-3	469-476	present	abstract[23]	giv[23]	_	_
7-4	477-482	study	abstract[23]	giv[23]	_	_
7-5	483-484	,	_	_	_	_
7-6	485-487	we	person	acc	ana	13-6
7-7	488-496	explored	_	_	_	_
7-8	497-500	the	abstract[25]	new[25]	coref	14-3[79_25]
7-9	501-513	relationship	abstract[25]	new[25]	_	_
7-10	514-521	between	abstract[25]	new[25]	_	_
7-11	522-528	target	abstract[25]|abstract[27]	new[25]|new[27]	coref	16-6[97_27]
7-12	529-537	mitotane	abstract[25]|abstract|abstract[27]	new[25]|giv|new[27]	coref	8-7
7-13	538-552	concentrations	abstract[25]|abstract[27]	new[25]|new[27]	_	_
7-14	553-556	and	abstract[25]	new[25]	_	_
7-15	557-564	patient	abstract[25]|abstract[28]	new[25]|giv[28]	_	_
7-16	565-572	outcome	abstract[25]|abstract[28]	new[25]|giv[28]	_	_
7-17	573-578	using	_	_	_	_
7-18	579-582	the	abstract[29]	new[29]	coref	13-8[68_29]
7-19	583-586	TTR	abstract[29]	new[29]	_	_
7-20	587-588	,	_	_	_	_
7-21	589-598	analogous	_	_	_	_
7-22	599-601	to	_	_	_	_
7-23	602-610	warfarin	person|abstract[31]	new|new[31]	coref	12-14[65_31]
7-24	611-620	treatment	abstract[31]	new[31]	_	_
7-25	621-622	.	_	_	_	_

#Text=Some previous studies used the peak mitotane level , which cannot give an adequate representation since it is a measurement at a single point in time .
8-1	623-627	Some	abstract[32]	giv[32]	coref	9-2[40_32]
8-2	628-636	previous	abstract[32]	giv[32]	_	_
8-3	637-644	studies	abstract[32]	giv[32]	_	_
8-4	645-649	used	_	_	_	_
8-5	650-653	the	abstract[35]	new[35]	coref	11-9[59_35]
8-6	654-658	peak	place|abstract[35]	new|new[35]	_	_
8-7	659-667	mitotane	abstract|abstract[35]	giv|new[35]	coref	9-8
8-8	668-673	level	abstract[35]	new[35]	_	_
8-9	674-675	,	abstract[35]	new[35]	_	_
8-10	676-681	which	abstract[35]	new[35]	_	_
8-11	682-688	cannot	abstract[35]	new[35]	_	_
8-12	689-693	give	abstract[35]	new[35]	_	_
8-13	694-696	an	abstract[35]|abstract[36]	new[35]|new[36]	ana	8-17[0_36]
8-14	697-705	adequate	abstract[35]|abstract[36]	new[35]|new[36]	_	_
8-15	706-720	representation	abstract[35]|abstract[36]	new[35]|new[36]	_	_
8-16	721-726	since	_	_	_	_
8-17	727-729	it	abstract	giv	coref	8-19[38_0]
8-18	730-732	is	_	_	_	_
8-19	733-734	a	abstract[38]	giv[38]	coref	13-16[71_38]
8-20	735-746	measurement	abstract[38]	giv[38]	_	_
8-21	747-749	at	abstract[38]	giv[38]	_	_
8-22	750-751	a	abstract[38]|abstract[39]	giv[38]|new[39]	coref	20-3[132_39]
8-23	752-758	single	abstract[38]|abstract[39]	giv[38]|new[39]	_	_
8-24	759-764	point	abstract[38]|abstract[39]	giv[38]|new[39]	_	_
8-25	765-767	in	abstract[38]|abstract[39]	giv[38]|new[39]	_	_
8-26	768-772	time	abstract[38]|abstract[39]	giv[38]|new[39]	_	_
8-27	773-774	.	_	_	_	_

#Text=In other studies , the percentage of mitotane measurements in a range was used , but this method has the caveat of being strongly dependent on the number of available measurements .
9-1	775-777	In	_	_	_	_
9-2	778-783	other	abstract[40]	giv[40]	_	_
9-3	784-791	studies	abstract[40]	giv[40]	_	_
9-4	792-793	,	_	_	_	_
9-5	794-797	the	abstract[41]	new[41]	coref	11-10[0_41]
9-6	798-808	percentage	abstract[41]	new[41]	_	_
9-7	809-811	of	abstract[41]	new[41]	_	_
9-8	812-820	mitotane	abstract[41]|abstract|abstract[43]	new[41]|giv|new[43]	coref|coref	9-30[48_43]|11-17
9-9	821-833	measurements	abstract[41]|abstract[43]	new[41]|new[43]	_	_
9-10	834-836	in	abstract[41]	new[41]	_	_
9-11	837-838	a	abstract[41]|abstract[44]	new[41]|new[44]	coref	19-25[129_44]
9-12	839-844	range	abstract[41]|abstract[44]	new[41]|new[44]	_	_
9-13	845-848	was	_	_	_	_
9-14	849-853	used	_	_	_	_
9-15	854-855	,	_	_	_	_
9-16	856-859	but	_	_	_	_
9-17	860-864	this	abstract[45]	new[45]	_	_
9-18	865-871	method	abstract[45]	new[45]	_	_
9-19	872-875	has	_	_	_	_
9-20	876-879	the	abstract[46]	new[46]	_	_
9-21	880-886	caveat	abstract[46]	new[46]	_	_
9-22	887-889	of	abstract[46]	new[46]	_	_
9-23	890-895	being	abstract[46]	new[46]	_	_
9-24	896-904	strongly	abstract[46]	new[46]	_	_
9-25	905-914	dependent	abstract[46]	new[46]	_	_
9-26	915-917	on	abstract[46]	new[46]	_	_
9-27	918-921	the	abstract[46]|abstract[47]	new[46]|new[47]	ana	10-1[0_47]
9-28	922-928	number	abstract[46]|abstract[47]	new[46]|new[47]	_	_
9-29	929-931	of	abstract[46]|abstract[47]	new[46]|new[47]	_	_
9-30	932-941	available	abstract[46]|abstract[47]|abstract[48]	new[46]|new[47]|giv[48]	_	_
9-31	942-954	measurements	abstract[46]|abstract[47]|abstract[48]	new[46]|new[47]|giv[48]	_	_
9-32	955-956	.	_	_	_	_

#Text=This may introduce a bias when comparing patients with different durations of follow-ups , which may be quite prolonged in the case of adjuvant therapy .
10-1	957-961	This	abstract	giv	_	_
10-2	962-965	may	_	_	_	_
10-3	966-975	introduce	_	_	_	_
10-4	976-977	a	abstract[50]	new[50]	_	_
10-5	978-982	bias	abstract[50]	new[50]	_	_
10-6	983-987	when	_	_	_	_
10-7	988-997	comparing	_	_	_	_
10-8	998-1006	patients	person[51]	giv[51]	coref	20-17[0_51]
10-9	1007-1011	with	person[51]	giv[51]	_	_
10-10	1012-1021	different	person[51]|time[52]	giv[51]|new[52]	_	_
10-11	1022-1031	durations	person[51]|time[52]	giv[51]|new[52]	_	_
10-12	1032-1034	of	person[51]|time[52]	giv[51]|new[52]	_	_
10-13	1035-1045	follow-ups	person[51]|time[52]|event	giv[51]|new[52]|new	_	_
10-14	1046-1047	,	person[51]|time[52]	giv[51]|new[52]	_	_
10-15	1048-1053	which	person[51]|time[52]	giv[51]|new[52]	_	_
10-16	1054-1057	may	person[51]|time[52]	giv[51]|new[52]	_	_
10-17	1058-1060	be	person[51]|time[52]	giv[51]|new[52]	_	_
10-18	1061-1066	quite	person[51]|time[52]	giv[51]|new[52]	_	_
10-19	1067-1076	prolonged	person[51]|time[52]	giv[51]|new[52]	_	_
10-20	1077-1079	in	person[51]|time[52]	giv[51]|new[52]	_	_
10-21	1080-1083	the	person[51]|time[52]|abstract[54]	giv[51]|new[52]|new[54]	_	_
10-22	1084-1088	case	person[51]|time[52]|abstract[54]	giv[51]|new[52]|new[54]	_	_
10-23	1089-1091	of	person[51]|time[52]|abstract[54]	giv[51]|new[52]|new[54]	_	_
10-24	1092-1100	adjuvant	person[51]|time[52]|abstract[54]|abstract|abstract[56]	giv[51]|new[52]|new[54]|new|giv[56]	coref	26-15[198_56]
10-25	1101-1108	therapy	person[51]|time[52]|abstract[54]|abstract[56]	giv[51]|new[52]|new[54]|giv[56]	_	_
10-26	1109-1110	.	_	_	_	_

#Text=Moreover , there is no evidence to define what percentage level identifies a good exposure to mitotane .
11-1	1111-1119	Moreover	_	_	_	_
11-2	1120-1121	,	_	_	_	_
11-3	1122-1127	there	_	_	_	_
11-4	1128-1130	is	_	_	_	_
11-5	1131-1133	no	abstract[57]	new[57]	_	_
11-6	1134-1142	evidence	abstract[57]	new[57]	_	_
11-7	1143-1145	to	abstract[57]	new[57]	_	_
11-8	1146-1152	define	abstract[57]	new[57]	_	_
11-9	1153-1157	what	abstract[57]|abstract[59]	new[57]|giv[59]	coref	16-19[100_59]
11-10	1158-1168	percentage	abstract[57]|abstract|abstract[59]	new[57]|giv|giv[59]	_	_
11-11	1169-1174	level	abstract[57]|abstract[59]	new[57]|giv[59]	_	_
11-12	1175-1185	identifies	abstract[57]	new[57]	_	_
11-13	1186-1187	a	abstract[57]|event[60]	new[57]|new[60]	coref	13-21[72_60]
11-14	1188-1192	good	abstract[57]|event[60]	new[57]|new[60]	_	_
11-15	1193-1201	exposure	abstract[57]|event[60]	new[57]|new[60]	_	_
11-16	1202-1204	to	abstract[57]|event[60]	new[57]|new[60]	_	_
11-17	1205-1213	mitotane	abstract[57]|event[60]|abstract	new[57]|new[60]|giv	coref	13-24
11-18	1214-1215	.	_	_	_	_

#Text=These methodological issues may have contributed to the discrepancy in the literature concerning adjuvant treatment .
12-1	1216-1221	These	abstract[62]	new[62]	_	_
12-2	1222-1236	methodological	abstract[62]	new[62]	_	_
12-3	1237-1243	issues	abstract[62]	new[62]	_	_
12-4	1244-1247	may	_	_	_	_
12-5	1248-1252	have	_	_	_	_
12-6	1253-1264	contributed	_	_	_	_
12-7	1265-1267	to	_	_	_	_
12-8	1268-1271	the	abstract[63]	new[63]	_	_
12-9	1272-1283	discrepancy	abstract[63]	new[63]	_	_
12-10	1284-1286	in	abstract[63]	new[63]	_	_
12-11	1287-1290	the	abstract[63]|abstract[64]	new[63]|new[64]	_	_
12-12	1291-1301	literature	abstract[63]|abstract[64]	new[63]|new[64]	_	_
12-13	1302-1312	concerning	abstract[63]|abstract[64]	new[63]|new[64]	_	_
12-14	1313-1321	adjuvant	abstract[63]|abstract[64]|abstract[65]	new[63]|new[64]|giv[65]	coref	16-13[98_65]
12-15	1322-1331	treatment	abstract[63]|abstract[64]|abstract[65]	new[63]|new[64]|giv[65]	_	_
12-16	1332-1333	.	_	_	_	_

#Text=In the present study , we calculated the TTR , which in our opinion gives a more adequate representation of chronic exposure to mitotane , and analyzed the results in a multivariate analysis without predefining arbitrary cutoff values .
13-1	1334-1336	In	_	_	_	_
13-2	1337-1340	the	abstract[66]	giv[66]	coref	25-22[0_66]
13-3	1341-1348	present	abstract[66]	giv[66]	_	_
13-4	1349-1354	study	abstract[66]	giv[66]	_	_
13-5	1355-1356	,	_	_	_	_
13-6	1357-1359	we	person	giv	ana	13-13
13-7	1360-1370	calculated	_	_	_	_
13-8	1371-1374	the	abstract[68]	giv[68]	coref	14-7[80_68]
13-9	1375-1378	TTR	abstract[68]	giv[68]	_	_
13-10	1379-1380	,	abstract[68]	giv[68]	_	_
13-11	1381-1386	which	abstract[68]	giv[68]	_	_
13-12	1387-1389	in	abstract[68]	giv[68]	_	_
13-13	1390-1393	our	abstract[68]|person|abstract[70]	giv[68]|giv|new[70]	ana	14-1
13-14	1394-1401	opinion	abstract[68]|abstract[70]	giv[68]|new[70]	_	_
13-15	1402-1407	gives	abstract[68]	giv[68]	_	_
13-16	1408-1409	a	abstract[68]|abstract[71]	giv[68]|giv[71]	_	_
13-17	1410-1414	more	abstract[68]|abstract[71]	giv[68]|giv[71]	_	_
13-18	1415-1423	adequate	abstract[68]|abstract[71]	giv[68]|giv[71]	_	_
13-19	1424-1438	representation	abstract[68]|abstract[71]	giv[68]|giv[71]	_	_
13-20	1439-1441	of	abstract[68]|abstract[71]	giv[68]|giv[71]	_	_
13-21	1442-1449	chronic	abstract[68]|abstract[71]|event[72]	giv[68]|giv[71]|giv[72]	_	_
13-22	1450-1458	exposure	abstract[68]|abstract[71]|event[72]	giv[68]|giv[71]|giv[72]	_	_
13-23	1459-1461	to	abstract[68]|abstract[71]|event[72]	giv[68]|giv[71]|giv[72]	_	_
13-24	1462-1470	mitotane	abstract[68]|abstract[71]|event[72]|abstract	giv[68]|giv[71]|giv[72]|giv	coref	15-8
13-25	1471-1472	,	_	_	_	_
13-26	1473-1476	and	_	_	_	_
13-27	1477-1485	analyzed	_	_	_	_
13-28	1486-1489	the	abstract[74]	new[74]	coref	32-15[254_74]
13-29	1490-1497	results	abstract[74]	new[74]	_	_
13-30	1498-1500	in	_	_	_	_
13-31	1501-1502	a	abstract[75]	new[75]	coref	32-9[252_75]
13-32	1503-1515	multivariate	abstract[75]	new[75]	_	_
13-33	1516-1524	analysis	abstract[75]	new[75]	_	_
13-34	1525-1532	without	_	_	_	_
13-35	1533-1544	predefining	_	_	_	_
13-36	1545-1554	arbitrary	abstract[77]	new[77]	_	_
13-37	1555-1561	cutoff	abstract|abstract[77]	new|new[77]	_	_
13-38	1562-1568	values	abstract[77]	new[77]	_	_
13-39	1569-1570	.	_	_	_	_

#Text=We found an inverse relationship between the TTR and risk of ACC recurrence , implying that the greater the TTR , the lower the risk .
14-1	1571-1573	We	person	giv	ana	16-17
14-2	1574-1579	found	_	_	_	_
14-3	1580-1582	an	abstract[79]	giv[79]	coref	23-3[157_79]
14-4	1583-1590	inverse	abstract[79]	giv[79]	_	_
14-5	1591-1603	relationship	abstract[79]	giv[79]	_	_
14-6	1604-1611	between	abstract[79]	giv[79]	_	_
14-7	1612-1615	the	abstract[79]|abstract[80]	giv[79]|giv[80]	coref	14-19[84_80]
14-8	1616-1619	TTR	abstract[79]|abstract[80]	giv[79]|giv[80]	_	_
14-9	1620-1623	and	abstract[79]	giv[79]	_	_
14-10	1624-1628	risk	abstract[79]|abstract[81]	giv[79]|new[81]	coref	14-22[85_81]
14-11	1629-1631	of	abstract[79]|abstract[81]	giv[79]|new[81]	_	_
14-12	1632-1635	ACC	abstract[79]|abstract[81]|organization|event[83]	giv[79]|new[81]|giv|giv[83]	coref|coref	17-17|17-17[112_83]
14-13	1636-1646	recurrence	abstract[79]|abstract[81]|event[83]	giv[79]|new[81]|giv[83]	_	_
14-14	1647-1648	,	_	_	_	_
14-15	1649-1657	implying	_	_	_	_
14-16	1658-1662	that	_	_	_	_
14-17	1663-1666	the	_	_	_	_
14-18	1667-1674	greater	_	_	_	_
14-19	1675-1678	the	abstract[84]	giv[84]	_	_
14-20	1679-1682	TTR	abstract[84]	giv[84]	_	_
14-21	1683-1684	,	_	_	_	_
14-22	1685-1688	the	abstract[85]	giv[85]	_	_
14-23	1689-1694	lower	abstract[85]	giv[85]	_	_
14-24	1695-1698	the	abstract[85]	giv[85]	_	_
14-25	1699-1703	risk	abstract[85]	giv[85]	_	_
14-26	1704-1705	.	_	_	_	_

#Text=This finding supports the clinical value of mitotane monitoring and the concept of target doses in the adjuvant setting .
15-1	1706-1710	This	abstract[86]	new[86]	coref	23-22[165_86]
15-2	1711-1718	finding	abstract[86]	new[86]	_	_
15-3	1719-1727	supports	_	_	_	_
15-4	1728-1731	the	abstract[87]	new[87]	_	_
15-5	1732-1740	clinical	abstract[87]	new[87]	_	_
15-6	1741-1746	value	abstract[87]	new[87]	_	_
15-7	1747-1749	of	abstract[87]	new[87]	_	_
15-8	1750-1758	mitotane	abstract[87]|abstract|abstract[89]	new[87]|giv|new[89]	coref|coref	16-7|21-24[147_89]
15-9	1759-1769	monitoring	abstract[87]|abstract[89]	new[87]|new[89]	_	_
15-10	1770-1773	and	_	_	_	_
15-11	1774-1777	the	abstract[90]	new[90]	coref	18-5[116_90]
15-12	1778-1785	concept	abstract[90]	new[90]	_	_
15-13	1786-1788	of	abstract[90]	new[90]	_	_
15-14	1789-1795	target	abstract[90]|abstract|abstract[92]	new[90]|new|new[92]	coref	24-3[174_92]
15-15	1796-1801	doses	abstract[90]|abstract[92]	new[90]|new[92]	_	_
15-16	1802-1804	in	abstract[90]|abstract[92]	new[90]|new[92]	_	_
15-17	1805-1808	the	abstract[90]|abstract[92]|abstract[94]	new[90]|new[92]|new[94]	ana	16-2[0_94]
15-18	1809-1817	adjuvant	abstract[90]|abstract[92]|person|abstract[94]	new[90]|new[92]|giv|new[94]	coref	25-8
15-19	1818-1825	setting	abstract[90]|abstract[92]|abstract[94]	new[90]|new[92]|new[94]	_	_
15-20	1826-1827	.	_	_	_	_

#Text=Although it is plausible that lower mitotane concentrations may be effective in an adjuvant treatment , we analyzed only the level of 14 mg/L , because this was the target in our practice .
16-1	1828-1836	Although	_	_	_	_
16-2	1837-1839	it	abstract	giv	ana	16-27
16-3	1840-1842	is	_	_	_	_
16-4	1843-1852	plausible	_	_	_	_
16-5	1853-1857	that	_	_	_	_
16-6	1858-1863	lower	abstract[97]	giv[97]	coref	17-6[108_97]
16-7	1864-1872	mitotane	abstract|abstract[97]	giv|giv[97]	coref	17-7
16-8	1873-1887	concentrations	abstract[97]	giv[97]	_	_
16-9	1888-1891	may	_	_	_	_
16-10	1892-1894	be	_	_	_	_
16-11	1895-1904	effective	_	_	_	_
16-12	1905-1907	in	_	_	_	_
16-13	1908-1910	an	abstract[98]	giv[98]	coref	19-13[0_98]
16-14	1911-1919	adjuvant	abstract[98]	giv[98]	_	_
16-15	1920-1929	treatment	abstract[98]	giv[98]	_	_
16-16	1930-1931	,	_	_	_	_
16-17	1932-1934	we	person	giv	ana	16-32
16-18	1935-1943	analyzed	_	_	_	_
16-19	1944-1948	only	abstract[100]	giv[100]	_	_
16-20	1949-1952	the	abstract[100]	giv[100]	_	_
16-21	1953-1958	level	abstract[100]	giv[100]	_	_
16-22	1959-1961	of	abstract[100]	giv[100]	_	_
16-23	1962-1964	14	abstract[100]|substance[101]	giv[100]|new[101]	_	_
16-24	1965-1969	mg/L	abstract[100]|substance[101]	giv[100]|new[101]	_	_
16-25	1970-1971	,	_	_	_	_
16-26	1972-1979	because	_	_	_	_
16-27	1980-1984	this	abstract	giv	coref	16-29[103_0]
16-28	1985-1988	was	_	_	_	_
16-29	1989-1992	the	abstract[103]	giv[103]	coref	19-26[0_103]
16-30	1993-1999	target	abstract[103]	giv[103]	_	_
16-31	2000-2002	in	abstract[103]	giv[103]	_	_
16-32	2003-2006	our	abstract[103]|person|abstract[105]	giv[103]|giv|new[105]	ana|coref	20-1|24-21[179_105]
16-33	2007-2015	practice	abstract[103]|abstract[105]	giv[103]|new[105]	_	_
16-34	2016-2017	.	_	_	_	_

#Text=The time needed to achieve target mitotane concentrations also has an impact on the risk of ACC recurrence : a longer time was associated with higher risk .
17-1	2018-2021	The	time[106]	new[106]	coref	17-20[113_106]
17-2	2022-2026	time	time[106]	new[106]	_	_
17-3	2027-2033	needed	time[106]	new[106]	_	_
17-4	2034-2036	to	time[106]	new[106]	_	_
17-5	2037-2044	achieve	time[106]|event	new[106]|new	coref|none	18-16[119_0]|17-5[0_119]
17-6	2045-2051	target	time[106]|abstract[108]	new[106]|giv[108]	coref	20-11[135_108]
17-7	2052-2060	mitotane	time[106]|abstract|abstract[108]	new[106]|giv|giv[108]	coref	18-8
17-8	2061-2075	concentrations	time[106]|abstract[108]	new[106]|giv[108]	_	_
17-9	2076-2080	also	_	_	_	_
17-10	2081-2084	has	_	_	_	_
17-11	2085-2087	an	abstract[109]	giv[109]	_	_
17-12	2088-2094	impact	abstract[109]	giv[109]	_	_
17-13	2095-2097	on	abstract[109]	giv[109]	_	_
17-14	2098-2101	the	abstract[109]|abstract[110]	giv[109]|new[110]	coref	17-26[114_110]
17-15	2102-2106	risk	abstract[109]|abstract[110]	giv[109]|new[110]	_	_
17-16	2107-2109	of	abstract[109]|abstract[110]	giv[109]|new[110]	_	_
17-17	2110-2113	ACC	abstract[109]|abstract[110]|organization|event[112]	giv[109]|new[110]|giv|giv[112]	coref|coref	20-22[0_112]|30-15
17-18	2114-2124	recurrence	abstract[109]|abstract[110]|event[112]	giv[109]|new[110]|giv[112]	_	_
17-19	2125-2126	:	_	_	_	_
17-20	2127-2128	a	time[113]	giv[113]	coref	19-19[127_113]
17-21	2129-2135	longer	time[113]	giv[113]	_	_
17-22	2136-2140	time	time[113]	giv[113]	_	_
17-23	2141-2144	was	_	_	_	_
17-24	2145-2155	associated	_	_	_	_
17-25	2156-2160	with	_	_	_	_
17-26	2161-2167	higher	abstract[114]	giv[114]	ana	18-1[0_114]
17-27	2168-2172	risk	abstract[114]	giv[114]	_	_
17-28	2173-2174	.	_	_	_	_

#Text=This is consistent with the concept that mitotane is a slow-acting drug in relation to the achievement of significant plasma levels .
18-1	2175-2179	This	abstract	giv	_	_
18-2	2180-2182	is	_	_	_	_
18-3	2183-2193	consistent	_	_	_	_
18-4	2194-2198	with	_	_	_	_
18-5	2199-2202	the	abstract[116]	giv[116]	coref	23-28[167_116]
18-6	2203-2210	concept	abstract[116]	giv[116]	_	_
18-7	2211-2215	that	abstract[116]	giv[116]	_	_
18-8	2216-2224	mitotane	abstract[116]|abstract|substance[118]	giv[116]|giv|new[118]	coref|coref	21-17|28-8[215_118]
18-9	2225-2227	is	abstract[116]|substance[118]	giv[116]|new[118]	_	_
18-10	2228-2229	a	abstract[116]|substance[118]	giv[116]|new[118]	_	_
18-11	2230-2241	slow-acting	abstract[116]|substance[118]	giv[116]|new[118]	_	_
18-12	2242-2246	drug	abstract[116]|substance[118]	giv[116]|new[118]	_	_
18-13	2247-2249	in	abstract[116]|substance[118]	giv[116]|new[118]	_	_
18-14	2250-2258	relation	abstract[116]|substance[118]	giv[116]|new[118]	_	_
18-15	2259-2261	to	abstract[116]|substance[118]	giv[116]|new[118]	_	_
18-16	2262-2265	the	abstract[116]|substance[118]|event[119]	giv[116]|new[118]|new[119]	_	_
18-17	2266-2277	achievement	abstract[116]|substance[118]|event[119]	giv[116]|new[118]|new[119]	_	_
18-18	2278-2280	of	abstract[116]|substance[118]|event[119]	giv[116]|new[118]|new[119]	_	_
18-19	2281-2292	significant	abstract[116]|substance[118]|event[119]|abstract[121]	giv[116]|new[118]|new[119]|new[121]	coref	21-17[144_121]
18-20	2293-2299	plasma	abstract[116]|substance[118]|event[119]|substance|abstract[121]	giv[116]|new[118]|new[119]|new|new[121]	coref	23-12
18-21	2300-2306	levels	abstract[116]|substance[118]|event[119]|abstract[121]	giv[116]|new[118]|new[119]|new[121]	_	_
18-22	2307-2308	.	_	_	_	_

#Text=Due to the very cautious dose titration in the starting phase of treatment employed in many centers , the time needed to get into the target range was exceedingly long .
19-1	2309-2312	Due	_	_	_	_
19-2	2313-2315	to	_	_	_	_
19-3	2316-2319	the	event[123]	new[123]	_	_
19-4	2320-2324	very	event[123]	new[123]	_	_
19-5	2325-2333	cautious	event[123]	new[123]	_	_
19-6	2334-2338	dose	abstract|event[123]	new|new[123]	coref	23-8[159_0]
19-7	2339-2348	titration	event[123]	new[123]	_	_
19-8	2349-2351	in	event[123]	new[123]	_	_
19-9	2352-2355	the	event[123]|abstract[124]	new[123]|new[124]	_	_
19-10	2356-2364	starting	event[123]|abstract[124]	new[123]|new[124]	_	_
19-11	2365-2370	phase	event[123]|abstract[124]	new[123]|new[124]	_	_
19-12	2371-2373	of	event[123]|abstract[124]	new[123]|new[124]	_	_
19-13	2374-2383	treatment	event[123]|abstract[124]|abstract	new[123]|new[124]|giv	coref	22-26
19-14	2384-2392	employed	event[123]	new[123]	_	_
19-15	2393-2395	in	event[123]	new[123]	_	_
19-16	2396-2400	many	event[123]|place[126]	new[123]|new[126]	coref	28-24[219_126]
19-17	2401-2408	centers	event[123]|place[126]	new[123]|new[126]	_	_
19-18	2409-2410	,	_	_	_	_
19-19	2411-2414	the	time[127]	giv[127]	coref	20-4[0_127]
19-20	2415-2419	time	time[127]	giv[127]	_	_
19-21	2420-2426	needed	time[127]	giv[127]	_	_
19-22	2427-2429	to	time[127]	giv[127]	_	_
19-23	2430-2433	get	time[127]	giv[127]	_	_
19-24	2434-2438	into	_	_	_	_
19-25	2439-2442	the	abstract[129]	giv[129]	_	_
19-26	2443-2449	target	abstract|abstract[129]	giv|giv[129]	coref	20-11
19-27	2450-2455	range	abstract[129]	giv[129]	_	_
19-28	2456-2459	was	_	_	_	_
19-29	2460-2471	exceedingly	_	_	_	_
19-30	2472-2476	long	_	_	_	_
19-31	2477-2478	.	_	_	_	_

#Text=We identified a time point at 17 months to achieve target concentrations , which significantly differentiates patients for their risk of recurrence .
20-1	2479-2481	We	person	giv	ana	23-1
20-2	2482-2492	identified	_	_	_	_
20-3	2493-2494	a	abstract[132]	giv[132]	_	_
20-4	2495-2499	time	time|abstract[132]	giv|giv[132]	coref	33-8[265_0]
20-5	2500-2505	point	abstract[132]	giv[132]	_	_
20-6	2506-2508	at	abstract[132]	giv[132]	_	_
20-7	2509-2511	17	abstract[132]|time[133]	giv[132]|new[133]	_	_
20-8	2512-2518	months	abstract[132]|time[133]	giv[132]|new[133]	_	_
20-9	2519-2521	to	_	_	_	_
20-10	2522-2529	achieve	_	_	_	_
20-11	2530-2536	target	abstract|abstract[135]	giv|giv[135]	coref	23-11[162_135]
20-12	2537-2551	concentrations	abstract[135]	giv[135]	_	_
20-13	2552-2553	,	abstract[135]	giv[135]	_	_
20-14	2554-2559	which	abstract[135]	giv[135]	_	_
20-15	2560-2573	significantly	abstract[135]	giv[135]	_	_
20-16	2574-2588	differentiates	abstract[135]	giv[135]	_	_
20-17	2589-2597	patients	abstract[135]|person	giv[135]|giv	ana	20-19
20-18	2598-2601	for	abstract[135]	giv[135]	_	_
20-19	2602-2607	their	abstract[135]|person|abstract[138]	giv[135]|giv|new[138]	coref	24-11[176_0]
20-20	2608-2612	risk	abstract[135]|abstract[138]	giv[135]|new[138]	_	_
20-21	2613-2615	of	abstract[135]|abstract[138]	giv[135]|new[138]	_	_
20-22	2616-2626	recurrence	abstract[135]|abstract[138]|event	giv[135]|new[138]|giv	coref	32-33[261_0]
20-23	2627-2628	.	_	_	_	_

#Text=The present findings call for a change in practice , aiming for a faster rise in mitotane levels and strengthening the value of mitotane monitoring .
21-1	2629-2632	The	abstract[140]	new[140]	coref	24-16[178_140]
21-2	2633-2640	present	abstract[140]	new[140]	_	_
21-3	2641-2649	findings	abstract[140]	new[140]	_	_
21-4	2650-2654	call	_	_	_	_
21-5	2655-2658	for	_	_	_	_
21-6	2659-2660	a	event[141]	new[141]	_	_
21-7	2661-2667	change	event[141]	new[141]	_	_
21-8	2668-2670	in	event[141]	new[141]	_	_
21-9	2671-2679	practice	event[141]	new[141]	_	_
21-10	2680-2681	,	_	_	_	_
21-11	2682-2688	aiming	_	_	_	_
21-12	2689-2692	for	_	_	_	_
21-13	2693-2694	a	event[142]	new[142]	_	_
21-14	2695-2701	faster	event[142]	new[142]	_	_
21-15	2702-2706	rise	event[142]	new[142]	_	_
21-16	2707-2709	in	event[142]	new[142]	_	_
21-17	2710-2718	mitotane	event[142]|abstract|abstract[144]	new[142]|giv|giv[144]	coref	21-24
21-18	2719-2725	levels	event[142]|abstract[144]	new[142]|giv[144]	_	_
21-19	2726-2729	and	_	_	_	_
21-20	2730-2743	strengthening	_	_	_	_
21-21	2744-2747	the	abstract[145]	new[145]	_	_
21-22	2748-2753	value	abstract[145]	new[145]	_	_
21-23	2754-2756	of	abstract[145]	new[145]	_	_
21-24	2757-2765	mitotane	abstract[145]|abstract|abstract[147]	new[145]|giv|giv[147]	coref	22-11
21-25	2766-2776	monitoring	abstract[145]|abstract[147]	new[145]|giv[147]	_	_
21-26	2777-2778	.	_	_	_	_

#Text=However , the potential danger of a rapid increment in mitotane dosing , which may result in important toxicity with consequent loss of compliance to treatment , should be considered .
22-1	2779-2786	However	_	_	_	_
22-2	2787-2788	,	_	_	_	_
22-3	2789-2792	the	abstract[148]	new[148]	_	_
22-4	2793-2802	potential	abstract[148]	new[148]	_	_
22-5	2803-2809	danger	abstract[148]	new[148]	_	_
22-6	2810-2812	of	abstract[148]	new[148]	_	_
22-7	2813-2814	a	abstract[148]|event[149]	new[148]|new[149]	_	_
22-8	2815-2820	rapid	abstract[148]|event[149]	new[148]|new[149]	_	_
22-9	2821-2830	increment	abstract[148]|event[149]	new[148]|new[149]	_	_
22-10	2831-2833	in	abstract[148]|event[149]	new[148]|new[149]	_	_
22-11	2834-2842	mitotane	abstract[148]|event[149]|abstract|substance[151]	new[148]|new[149]|giv|new[151]	coref	23-8
22-12	2843-2849	dosing	abstract[148]|event[149]|substance[151]	new[148]|new[149]|new[151]	_	_
22-13	2850-2851	,	abstract[148]	new[148]	_	_
22-14	2852-2857	which	abstract[148]	new[148]	_	_
22-15	2858-2861	may	abstract[148]	new[148]	_	_
22-16	2862-2868	result	abstract[148]	new[148]	_	_
22-17	2869-2871	in	abstract[148]	new[148]	_	_
22-18	2872-2881	important	abstract[148]|abstract[152]	new[148]|new[152]	coref	25-5[182_152]
22-19	2882-2890	toxicity	abstract[148]|abstract[152]	new[148]|new[152]	_	_
22-20	2891-2895	with	abstract[148]|abstract[152]	new[148]|new[152]	_	_
22-21	2896-2906	consequent	abstract[148]|abstract[152]|event[153]	new[148]|new[152]|new[153]	_	_
22-22	2907-2911	loss	abstract[148]|abstract[152]|event[153]	new[148]|new[152]|new[153]	_	_
22-23	2912-2914	of	abstract[148]|abstract[152]|event[153]	new[148]|new[152]|new[153]	_	_
22-24	2915-2925	compliance	abstract[148]|abstract[152]|event[153]|abstract[154]	new[148]|new[152]|new[153]|new[154]	_	_
22-25	2926-2928	to	abstract[148]|abstract[152]|event[153]|abstract[154]	new[148]|new[152]|new[153]|new[154]	_	_
22-26	2929-2938	treatment	abstract[148]|abstract[152]|event[153]|abstract[154]|abstract	new[148]|new[152]|new[153]|new[154]|giv	coref	23-19
22-27	2939-2940	,	_	_	_	_
22-28	2941-2947	should	_	_	_	_
22-29	2948-2950	be	_	_	_	_
22-30	2951-2961	considered	_	_	_	_
22-31	2962-2963	.	_	_	_	_

#Text=We found only a weak relationship between mitotane dose and its plasma concentrations during the first phase of treatment , and this finding is in agreement with the concept that individual differences in mitotane metabolism and other still unknown factors influence plasma concentrations .
23-1	2964-2966	We	person	giv	ana	25-2
23-2	2967-2972	found	_	_	_	_
23-3	2973-2977	only	abstract[157]	giv[157]	ana	23-11[0_157]
23-4	2978-2979	a	abstract[157]	giv[157]	_	_
23-5	2980-2984	weak	abstract[157]	giv[157]	_	_
23-6	2985-2997	relationship	abstract[157]	giv[157]	_	_
23-7	2998-3005	between	abstract[157]	giv[157]	_	_
23-8	3006-3014	mitotane	abstract[157]|abstract|abstract[159]	giv[157]|giv|giv[159]	coref	23-34
23-9	3015-3019	dose	abstract[157]|abstract[159]	giv[157]|giv[159]	_	_
23-10	3020-3023	and	abstract[157]	giv[157]	_	_
23-11	3024-3027	its	abstract[157]|abstract|abstract[162]	giv[157]|giv|giv[162]	coref	23-42[173_162]
23-12	3028-3034	plasma	abstract[157]|substance|abstract[162]	giv[157]|giv|giv[162]	coref	23-42
23-13	3035-3049	concentrations	abstract[157]|abstract[162]	giv[157]|giv[162]	_	_
23-14	3050-3056	during	abstract[157]	giv[157]	_	_
23-15	3057-3060	the	abstract[157]|abstract[163]	giv[157]|new[163]	coref	26-39[205_163]
23-16	3061-3066	first	abstract[157]|abstract[163]	giv[157]|new[163]	_	_
23-17	3067-3072	phase	abstract[157]|abstract[163]	giv[157]|new[163]	_	_
23-18	3073-3075	of	abstract[157]|abstract[163]	giv[157]|new[163]	_	_
23-19	3076-3085	treatment	abstract[157]|abstract[163]|abstract	giv[157]|new[163]|giv	coref	26-6
23-20	3086-3087	,	_	_	_	_
23-21	3088-3091	and	_	_	_	_
23-22	3092-3096	this	abstract[165]	giv[165]	_	_
23-23	3097-3104	finding	abstract[165]	giv[165]	_	_
23-24	3105-3107	is	_	_	_	_
23-25	3108-3110	in	_	_	_	_
23-26	3111-3120	agreement	event[166]	new[166]	_	_
23-27	3121-3125	with	event[166]	new[166]	_	_
23-28	3126-3129	the	event[166]|abstract[167]	new[166]|giv[167]	_	_
23-29	3130-3137	concept	event[166]|abstract[167]	new[166]|giv[167]	_	_
23-30	3138-3142	that	event[166]|abstract[167]	new[166]|giv[167]	_	_
23-31	3143-3153	individual	event[166]|abstract[167]|abstract[168]	new[166]|giv[167]|new[168]	_	_
23-32	3154-3165	differences	event[166]|abstract[167]|abstract[168]	new[166]|giv[167]|new[168]	_	_
23-33	3166-3168	in	event[166]|abstract[167]|abstract[168]	new[166]|giv[167]|new[168]	_	_
23-34	3169-3177	mitotane	event[166]|abstract[167]|abstract[168]|abstract|abstract[170]	new[166]|giv[167]|new[168]|giv|new[170]	coref|coref	25-8[184_0]|29-32[228_170]
23-35	3178-3188	metabolism	event[166]|abstract[167]|abstract[168]|abstract[170]	new[166]|giv[167]|new[168]|new[170]	_	_
23-36	3189-3192	and	event[166]|abstract[167]|abstract[168]	new[166]|giv[167]|new[168]	_	_
23-37	3193-3198	other	event[166]|abstract[167]|abstract[168]|abstract[171]	new[166]|giv[167]|new[168]|new[171]	coref	29-29[226_171]
23-38	3199-3204	still	event[166]|abstract[167]|abstract[168]|abstract[171]	new[166]|giv[167]|new[168]|new[171]	_	_
23-39	3205-3212	unknown	event[166]|abstract[167]|abstract[168]|abstract[171]	new[166]|giv[167]|new[168]|new[171]	_	_
23-40	3213-3220	factors	event[166]|abstract[167]|abstract[168]|abstract[171]	new[166]|giv[167]|new[168]|new[171]	_	_
23-41	3221-3230	influence	event[166]|abstract[167]	new[166]|giv[167]	_	_
23-42	3231-3237	plasma	event[166]|abstract[167]|substance|abstract[173]	new[166]|giv[167]|giv|giv[173]	coref	29-19[224_173]
23-43	3238-3252	concentrations	event[166]|abstract[167]|abstract[173]	new[166]|giv[167]|giv[173]	_	_
23-44	3253-3254	.	_	_	_	_

#Text=Interestingly , higher doses were employed in men and in patients with greater BMI and these novel findings matter for clinical practice .
24-1	3255-3268	Interestingly	_	_	_	_
24-2	3269-3270	,	_	_	_	_
24-3	3271-3277	higher	abstract[174]	giv[174]	coref	26-24[200_174]
24-4	3278-3283	doses	abstract[174]	giv[174]	_	_
24-5	3284-3288	were	_	_	_	_
24-6	3289-3297	employed	_	_	_	_
24-7	3298-3300	in	_	_	_	_
24-8	3301-3304	men	person	new	_	_
24-9	3305-3308	and	_	_	_	_
24-10	3309-3311	in	_	_	_	_
24-11	3312-3320	patients	person[176]	giv[176]	coref	25-29[191_176]
24-12	3321-3325	with	person[176]	giv[176]	_	_
24-13	3326-3333	greater	person[176]|abstract[177]	giv[176]|new[177]	_	_
24-14	3334-3337	BMI	person[176]|abstract[177]	giv[176]|new[177]	_	_
24-15	3338-3341	and	_	_	_	_
24-16	3342-3347	these	abstract[178]	giv[178]	_	_
24-17	3348-3353	novel	abstract[178]	giv[178]	_	_
24-18	3354-3362	findings	abstract[178]	giv[178]	_	_
24-19	3363-3369	matter	_	_	_	_
24-20	3370-3373	for	_	_	_	_
24-21	3374-3382	clinical	abstract[179]	giv[179]	coref	31-28[249_179]
24-22	3383-3391	practice	abstract[179]	giv[179]	_	_
24-23	3392-3393	.	_	_	_	_

#Text=In our cohort , toxicity associated with adjuvant mitotane was acceptable , though we acknowledge the fact that due to the study inclusion criteria we did not capture the patients who eventually discontinued mitotane in the first six months .
25-1	3394-3396	In	_	_	_	_
25-2	3397-3400	our	person|object[181]	giv|new[181]	ana	25-14
25-3	3401-3407	cohort	object[181]	new[181]	_	_
25-4	3408-3409	,	_	_	_	_
25-5	3410-3418	toxicity	abstract[182]	giv[182]	coref	26-1[194_182]
25-6	3419-3429	associated	abstract[182]	giv[182]	_	_
25-7	3430-3434	with	abstract[182]	giv[182]	_	_
25-8	3435-3443	adjuvant	abstract[182]|person|abstract[184]	giv[182]|giv|giv[184]	coref|coref	25-34[0_184]|27-13
25-9	3444-3452	mitotane	abstract[182]|abstract[184]	giv[182]|giv[184]	_	_
25-10	3453-3456	was	_	_	_	_
25-11	3457-3467	acceptable	_	_	_	_
25-12	3468-3469	,	_	_	_	_
25-13	3470-3476	though	_	_	_	_
25-14	3477-3479	we	person	giv	ana	25-25
25-15	3480-3491	acknowledge	_	_	_	_
25-16	3492-3495	the	abstract[186]	new[186]	_	_
25-17	3496-3500	fact	abstract[186]	new[186]	_	_
25-18	3501-3505	that	abstract[186]	new[186]	_	_
25-19	3506-3509	due	abstract[186]	new[186]	_	_
25-20	3510-3512	to	abstract[186]	new[186]	_	_
25-21	3513-3516	the	abstract[186]|abstract[189]	new[186]|new[189]	coref	33-1[263_189]
25-22	3517-3522	study	abstract[186]|abstract|abstract[189]	new[186]|giv|new[189]	coref	27-3[206_0]
25-23	3523-3532	inclusion	abstract[186]|person|abstract[189]	new[186]|new|new[189]	coref	33-2
25-24	3533-3541	criteria	abstract[186]|abstract[189]	new[186]|new[189]	_	_
25-25	3542-3544	we	abstract[186]|person	new[186]|giv	ana	32-3
25-26	3545-3548	did	abstract[186]	new[186]	_	_
25-27	3549-3552	not	abstract[186]	new[186]	_	_
25-28	3553-3560	capture	abstract[186]|event	new[186]|new	coref|none	31-4[243_0]|25-28[0_243]
25-29	3561-3564	the	abstract[186]|person[191]	new[186]|giv[191]	coref	26-11[197_191]
25-30	3565-3573	patients	abstract[186]|person[191]	new[186]|giv[191]	_	_
25-31	3574-3577	who	abstract[186]|person[191]	new[186]|giv[191]	_	_
25-32	3578-3588	eventually	abstract[186]|person[191]	new[186]|giv[191]	_	_
25-33	3589-3601	discontinued	abstract[186]|person[191]	new[186]|giv[191]	_	_
25-34	3602-3610	mitotane	abstract[186]|person[191]|abstract	new[186]|giv[191]|giv	coref	27-13[209_0]
25-35	3611-3613	in	abstract[186]|person[191]	new[186]|giv[191]	_	_
25-36	3614-3617	the	abstract[186]|person[191]|time[193]	new[186]|giv[191]|new[193]	coref	27-16[210_193]
25-37	3618-3623	first	abstract[186]|person[191]|time[193]	new[186]|giv[191]|new[193]	_	_
25-38	3624-3627	six	abstract[186]|person[191]|time[193]	new[186]|giv[191]|new[193]	_	_
25-39	3628-3634	months	abstract[186]|person[191]|time[193]	new[186]|giv[191]|new[193]	_	_
25-40	3635-3636	.	_	_	_	_

#Text=Severe toxicity leading to permanent treatment discontinuation was recorded in only five patients on chronic therapy , and this is likely due to the low doses ( median dose of 2 g/day ) used to continue treatment in the maintenance phase .
26-1	3637-3643	Severe	abstract[194]	giv[194]	coref	29-13[222_194]
26-2	3644-3652	toxicity	abstract[194]	giv[194]	_	_
26-3	3653-3660	leading	abstract[194]	giv[194]	_	_
26-4	3661-3663	to	abstract[194]	giv[194]	_	_
26-5	3664-3673	permanent	abstract[194]|event[196]	giv[194]|new[196]	ana	26-19[0_196]
26-6	3674-3683	treatment	abstract[194]|abstract|event[196]	giv[194]|giv|new[196]	coref	26-37
26-7	3684-3699	discontinuation	abstract[194]|event[196]	giv[194]|new[196]	_	_
26-8	3700-3703	was	_	_	_	_
26-9	3704-3712	recorded	_	_	_	_
26-10	3713-3715	in	_	_	_	_
26-11	3716-3720	only	person[197]	giv[197]	coref	27-8[207_197]
26-12	3721-3725	five	person[197]	giv[197]	_	_
26-13	3726-3734	patients	person[197]	giv[197]	_	_
26-14	3735-3737	on	person[197]	giv[197]	_	_
26-15	3738-3745	chronic	person[197]|abstract[198]	giv[197]|giv[198]	_	_
26-16	3746-3753	therapy	person[197]|abstract[198]	giv[197]|giv[198]	_	_
26-17	3754-3755	,	_	_	_	_
26-18	3756-3759	and	_	_	_	_
26-19	3760-3764	this	event	giv	_	_
26-20	3765-3767	is	_	_	_	_
26-21	3768-3774	likely	_	_	_	_
26-22	3775-3778	due	_	_	_	_
26-23	3779-3781	to	_	_	_	_
26-24	3782-3785	the	abstract[200]	giv[200]	appos	26-28[201_200]
26-25	3786-3789	low	abstract[200]	giv[200]	_	_
26-26	3790-3795	doses	abstract[200]	giv[200]	_	_
26-27	3796-3797	(	_	_	_	_
26-28	3798-3804	median	abstract[201]	giv[201]	_	_
26-29	3805-3809	dose	abstract[201]	giv[201]	_	_
26-30	3810-3812	of	abstract[201]	giv[201]	_	_
26-31	3813-3814	2	abstract[201]|abstract[202]	giv[201]|new[202]	_	_
26-32	3815-3820	g/day	abstract[201]|abstract[202]	giv[201]|new[202]	_	_
26-33	3821-3822	)	_	_	_	_
26-34	3823-3827	used	_	_	_	_
26-35	3828-3830	to	_	_	_	_
26-36	3831-3839	continue	_	_	_	_
26-37	3840-3849	treatment	abstract	giv	coref	27-20
26-38	3850-3852	in	_	_	_	_
26-39	3853-3856	the	abstract[205]	giv[205]	_	_
26-40	3857-3868	maintenance	abstract|abstract[205]	new|giv[205]	_	_
26-41	3869-3874	phase	abstract[205]	giv[205]	_	_
26-42	3875-3876	.	_	_	_	_

#Text=Thus , the present study shows that a few patients cannot tolerate adjuvant mitotane following the first months of treatment , proving than a careful follow-up is necessary .
27-1	3877-3881	Thus	_	_	_	_
27-2	3882-3883	,	_	_	_	_
27-3	3884-3887	the	abstract[206]	giv[206]	coref	30-3[230_206]
27-4	3888-3895	present	abstract[206]	giv[206]	_	_
27-5	3896-3901	study	abstract[206]	giv[206]	_	_
27-6	3902-3907	shows	_	_	_	_
27-7	3908-3912	that	_	_	_	_
27-8	3913-3914	a	person[207]	giv[207]	coref	28-20[0_207]
27-9	3915-3918	few	person[207]	giv[207]	_	_
27-10	3919-3927	patients	person[207]	giv[207]	_	_
27-11	3928-3934	cannot	_	_	_	_
27-12	3935-3943	tolerate	_	_	_	_
27-13	3944-3952	adjuvant	person|abstract[209]	giv|giv[209]	coref	28-2[0_209]
27-14	3953-3961	mitotane	abstract[209]	giv[209]	_	_
27-15	3962-3971	following	_	_	_	_
27-16	3972-3975	the	time[210]	giv[210]	coref	32-26[257_210]
27-17	3976-3981	first	time[210]	giv[210]	_	_
27-18	3982-3988	months	time[210]	giv[210]	_	_
27-19	3989-3991	of	time[210]	giv[210]	_	_
27-20	3992-4001	treatment	time[210]|abstract	giv[210]|giv	coref	28-14[217_0]
27-21	4002-4003	,	_	_	_	_
27-22	4004-4011	proving	_	_	_	_
27-23	4012-4016	than	_	_	_	_
27-24	4017-4018	a	event[212]	new[212]	_	_
27-25	4019-4026	careful	event[212]	new[212]	_	_
27-26	4027-4036	follow-up	event[212]	new[212]	_	_
27-27	4037-4039	is	_	_	_	_
27-28	4040-4049	necessary	_	_	_	_
27-29	4050-4051	.	_	_	_	_

#Text=Despite mitotane having a reputation for being a challenging drug to manage , adjuvant mitotane treatment is feasible when patients are managed in expert centers .
28-1	4052-4059	Despite	_	_	_	_
28-2	4060-4068	mitotane	abstract	giv	coref	28-15
28-3	4069-4075	having	_	_	_	_
28-4	4076-4077	a	abstract[214]	new[214]	_	_
28-5	4078-4088	reputation	abstract[214]	new[214]	_	_
28-6	4089-4092	for	_	_	_	_
28-7	4093-4098	being	_	_	_	_
28-8	4099-4100	a	substance[215]	giv[215]	coref	29-9[221_215]
28-9	4101-4112	challenging	substance[215]	giv[215]	_	_
28-10	4113-4117	drug	substance[215]	giv[215]	_	_
28-11	4118-4120	to	substance[215]	giv[215]	_	_
28-12	4121-4127	manage	substance[215]	giv[215]	_	_
28-13	4128-4129	,	_	_	_	_
28-14	4130-4138	adjuvant	abstract[217]	giv[217]	coref	30-11[233_217]
28-15	4139-4147	mitotane	abstract|abstract[217]	giv|giv[217]	coref	29-22
28-16	4148-4157	treatment	abstract[217]	giv[217]	_	_
28-17	4158-4160	is	_	_	_	_
28-18	4161-4169	feasible	_	_	_	_
28-19	4170-4174	when	_	_	_	_
28-20	4175-4183	patients	person	giv	coref	29-3[220_0]
28-21	4184-4187	are	_	_	_	_
28-22	4188-4195	managed	_	_	_	_
28-23	4196-4198	in	_	_	_	_
28-24	4199-4205	expert	place[219]	giv[219]	_	_
28-25	4206-4213	centers	place[219]	giv[219]	_	_
28-26	4214-4215	.	_	_	_	_

#Text=However , some patients were unable to tolerate the drug , exhibiting neurological toxicity even when exposed to “ normal ” mitotane concentrations , confirming the relevance of individual factors in mitotane metabolism .
29-1	4216-4223	However	_	_	_	_
29-2	4224-4225	,	_	_	_	_
29-3	4226-4230	some	person[220]	giv[220]	coref	30-15[235_220]
29-4	4231-4239	patients	person[220]	giv[220]	_	_
29-5	4240-4244	were	_	_	_	_
29-6	4245-4251	unable	_	_	_	_
29-7	4252-4254	to	_	_	_	_
29-8	4255-4263	tolerate	_	_	_	_
29-9	4264-4267	the	substance[221]	giv[221]	_	_
29-10	4268-4272	drug	substance[221]	giv[221]	_	_
29-11	4273-4274	,	_	_	_	_
29-12	4275-4285	exhibiting	_	_	_	_
29-13	4286-4298	neurological	abstract[222]	giv[222]	_	_
29-14	4299-4307	toxicity	abstract[222]	giv[222]	_	_
29-15	4308-4312	even	_	_	_	_
29-16	4313-4317	when	_	_	_	_
29-17	4318-4325	exposed	_	_	_	_
29-18	4326-4328	to	_	_	_	_
29-19	4329-4330	“	abstract[224]	giv[224]	_	_
29-20	4331-4337	normal	abstract[224]	giv[224]	_	_
29-21	4338-4339	”	abstract[224]	giv[224]	_	_
29-22	4340-4348	mitotane	abstract|abstract[224]	giv|giv[224]	coref	29-32
29-23	4349-4363	concentrations	abstract[224]	giv[224]	_	_
29-24	4364-4365	,	_	_	_	_
29-25	4366-4376	confirming	_	_	_	_
29-26	4377-4380	the	abstract[225]	new[225]	_	_
29-27	4381-4390	relevance	abstract[225]	new[225]	_	_
29-28	4391-4393	of	abstract[225]	new[225]	_	_
29-29	4394-4404	individual	abstract[225]|abstract[226]	new[225]|giv[226]	_	_
29-30	4405-4412	factors	abstract[225]|abstract[226]	new[225]|giv[226]	_	_
29-31	4413-4415	in	abstract[225]|abstract[226]	new[225]|giv[226]	_	_
29-32	4416-4424	mitotane	abstract[225]|abstract[226]|abstract|abstract[228]	new[225]|giv[226]|giv|giv[228]	coref	30-12
29-33	4425-4435	metabolism	abstract[225]|abstract[226]|abstract[228]	new[225]|giv[226]|giv[228]	_	_
29-34	4436-4437	.	_	_	_	_

#Text=Strengths of the present study are the thorough characterization of adjuvant mitotane treatment of ACC patients following surgical removal of the tumor and the large data set , considering the rarity of the disease .
30-1	4438-4447	Strengths	abstract[229]	new[229]	coref	30-7[231_229]
30-2	4448-4450	of	abstract[229]	new[229]	_	_
30-3	4451-4454	the	abstract[229]|abstract[230]	new[229]|giv[230]	coref	33-5[264_230]
30-4	4455-4462	present	abstract[229]|abstract[230]	new[229]|giv[230]	_	_
30-5	4463-4468	study	abstract[229]|abstract[230]	new[229]|giv[230]	_	_
30-6	4469-4472	are	_	_	_	_
30-7	4473-4476	the	abstract[231]	giv[231]	_	_
30-8	4477-4485	thorough	abstract[231]	giv[231]	_	_
30-9	4486-4502	characterization	abstract[231]	giv[231]	_	_
30-10	4503-4505	of	abstract[231]	giv[231]	_	_
30-11	4506-4514	adjuvant	abstract[231]|abstract[233]	giv[231]|giv[233]	coref	31-9[246_233]
30-12	4515-4523	mitotane	abstract[231]|abstract|abstract[233]	giv[231]|giv|giv[233]	coref	31-9
30-13	4524-4533	treatment	abstract[231]|abstract[233]	giv[231]|giv[233]	_	_
30-14	4534-4536	of	abstract[231]|abstract[233]	giv[231]|giv[233]	_	_
30-15	4537-4540	ACC	abstract[231]|abstract[233]|organization|person[235]	giv[231]|giv[233]|giv|giv[235]	coref|coref	32-21[255_235]|32-34
30-16	4541-4549	patients	abstract[231]|abstract[233]|person[235]	giv[231]|giv[233]|giv[235]	_	_
30-17	4550-4559	following	abstract[231]	giv[231]	_	_
30-18	4560-4568	surgical	abstract[231]|event[236]	giv[231]|new[236]	ana	31-1[0_236]
30-19	4569-4576	removal	abstract[231]|event[236]	giv[231]|new[236]	_	_
30-20	4577-4579	of	abstract[231]|event[236]	giv[231]|new[236]	_	_
30-21	4580-4583	the	abstract[231]|event[236]|object[237]	giv[231]|new[236]|new[237]	_	_
30-22	4584-4589	tumor	abstract[231]|event[236]|object[237]	giv[231]|new[236]|new[237]	_	_
30-23	4590-4593	and	abstract[231]	giv[231]	_	_
30-24	4594-4597	the	abstract[231]|abstract[239]	giv[231]|new[239]	_	_
30-25	4598-4603	large	abstract[231]|abstract[239]	giv[231]|new[239]	_	_
30-26	4604-4608	data	abstract[231]|abstract|abstract[239]	giv[231]|new|new[239]	_	_
30-27	4609-4612	set	abstract[231]|abstract[239]	giv[231]|new[239]	_	_
30-28	4613-4614	,	abstract[231]|abstract[239]	giv[231]|new[239]	_	_
30-29	4615-4626	considering	abstract[231]|abstract[239]	giv[231]|new[239]	_	_
30-30	4627-4630	the	abstract[231]|abstract[239]|abstract[240]	giv[231]|new[239]|new[240]	_	_
30-31	4631-4637	rarity	abstract[231]|abstract[239]|abstract[240]	giv[231]|new[239]|new[240]	_	_
30-32	4638-4640	of	abstract[231]|abstract[239]|abstract[240]	giv[231]|new[239]|new[240]	_	_
30-33	4641-4644	the	abstract[231]|abstract[239]|abstract[240]|abstract[241]	giv[231]|new[239]|new[240]|new[241]	_	_
30-34	4645-4652	disease	abstract[231]|abstract[239]|abstract[240]|abstract[241]	giv[231]|new[239]|new[240]|new[241]	_	_
30-35	4653-4654	.	_	_	_	_

#Text=This allowed for the capture of details of mitotane treatment that were not available in previous studies and led to observations that may be useful to informing future practice .
31-1	4655-4659	This	event	giv	_	_
31-2	4660-4667	allowed	_	_	_	_
31-3	4668-4671	for	_	_	_	_
31-4	4672-4675	the	event[243]	new[243]	_	_
31-5	4676-4683	capture	event[243]	new[243]	_	_
31-6	4684-4686	of	event[243]	new[243]	_	_
31-7	4687-4694	details	event[243]|abstract[244]	new[243]|new[244]	_	_
31-8	4695-4697	of	event[243]|abstract[244]	new[243]|new[244]	_	_
31-9	4698-4706	mitotane	event[243]|abstract[244]|abstract|abstract[246]	new[243]|new[244]|giv|giv[246]	coref	32-24[0_246]
31-10	4707-4716	treatment	event[243]|abstract[244]|abstract[246]	new[243]|new[244]|giv[246]	_	_
31-11	4717-4721	that	event[243]|abstract[244]	new[243]|new[244]	_	_
31-12	4722-4726	were	event[243]|abstract[244]	new[243]|new[244]	_	_
31-13	4727-4730	not	event[243]|abstract[244]	new[243]|new[244]	_	_
31-14	4731-4740	available	event[243]|abstract[244]	new[243]|new[244]	_	_
31-15	4741-4743	in	event[243]|abstract[244]	new[243]|new[244]	_	_
31-16	4744-4752	previous	event[243]|abstract[244]|abstract[247]	new[243]|new[244]|new[247]	_	_
31-17	4753-4760	studies	event[243]|abstract[244]|abstract[247]	new[243]|new[244]|new[247]	_	_
31-18	4761-4764	and	_	_	_	_
31-19	4765-4768	led	_	_	_	_
31-20	4769-4771	to	_	_	_	_
31-21	4772-4784	observations	abstract[248]	new[248]	_	_
31-22	4785-4789	that	abstract[248]	new[248]	_	_
31-23	4790-4793	may	abstract[248]	new[248]	_	_
31-24	4794-4796	be	abstract[248]	new[248]	_	_
31-25	4797-4803	useful	abstract[248]	new[248]	_	_
31-26	4804-4806	to	_	_	_	_
31-27	4807-4816	informing	_	_	_	_
31-28	4817-4823	future	abstract[249]	giv[249]	_	_
31-29	4824-4832	practice	abstract[249]	giv[249]	_	_
31-30	4833-4834	.	_	_	_	_

#Text=However , we should acknowledge the limits of a retrospective analysis , and that our results are not generalizable to patients who discontinue treatment within six months for intolerability or patients with early ACC recurrence .
32-1	4835-4842	However	_	_	_	_
32-2	4843-4844	,	_	_	_	_
32-3	4845-4847	we	person	giv	ana	32-15
32-4	4848-4854	should	_	_	_	_
32-5	4855-4866	acknowledge	_	_	_	_
32-6	4867-4870	the	abstract[251]	new[251]	_	_
32-7	4871-4877	limits	abstract[251]	new[251]	_	_
32-8	4878-4880	of	abstract[251]	new[251]	_	_
32-9	4881-4882	a	abstract[251]|abstract[252]	new[251]|giv[252]	_	_
32-10	4883-4896	retrospective	abstract[251]|abstract[252]	new[251]|giv[252]	_	_
32-11	4897-4905	analysis	abstract[251]|abstract[252]	new[251]|giv[252]	_	_
32-12	4906-4907	,	_	_	_	_
32-13	4908-4911	and	_	_	_	_
32-14	4912-4916	that	_	_	_	_
32-15	4917-4920	our	person|abstract[254]	giv|giv[254]	ana	33-18
32-16	4921-4928	results	abstract[254]	giv[254]	_	_
32-17	4929-4932	are	_	_	_	_
32-18	4933-4936	not	_	_	_	_
32-19	4937-4950	generalizable	_	_	_	_
32-20	4951-4953	to	_	_	_	_
32-21	4954-4962	patients	person[255]	giv[255]	coref	32-31[259_255]
32-22	4963-4966	who	person[255]	giv[255]	_	_
32-23	4967-4978	discontinue	person[255]	giv[255]	_	_
32-24	4979-4988	treatment	person[255]|abstract	giv[255]|giv	_	_
32-25	4989-4995	within	person[255]	giv[255]	_	_
32-26	4996-4999	six	person[255]|time[257]	giv[255]|giv[257]	coref	33-12[266_257]
32-27	5000-5006	months	person[255]|time[257]	giv[255]|giv[257]	_	_
32-28	5007-5010	for	person[255]	giv[255]	_	_
32-29	5011-5025	intolerability	person[255]|abstract	giv[255]|new	_	_
32-30	5026-5028	or	person[255]	giv[255]	_	_
32-31	5029-5037	patients	person[255]|person[259]	giv[255]|giv[259]	_	_
32-32	5038-5042	with	person[255]|person[259]	giv[255]|giv[259]	_	_
32-33	5043-5048	early	person[255]|person[259]|event[261]	giv[255]|giv[259]|giv[261]	_	_
32-34	5049-5052	ACC	person[255]|person[259]|organization|event[261]	giv[255]|giv[259]|giv|giv[261]	coref	33-25[270_0]
32-35	5053-5063	recurrence	person[255]|person[259]|event[261]	giv[255]|giv[259]|giv[261]	_	_
32-36	5064-5065	.	_	_	_	_

#Text=The inclusion criteria of the study produced an immortal time of six months that may have enriched our series of a higher number of low-risk ACC compared to recently published series .
33-1	5066-5069	The	abstract[263]	giv[263]	_	_
33-2	5070-5079	inclusion	person|abstract[263]	giv|giv[263]	_	_
33-3	5080-5088	criteria	abstract[263]	giv[263]	_	_
33-4	5089-5091	of	abstract[263]	giv[263]	_	_
33-5	5092-5095	the	abstract[263]|abstract[264]	giv[263]|giv[264]	_	_
33-6	5096-5101	study	abstract[263]|abstract[264]	giv[263]|giv[264]	_	_
33-7	5102-5110	produced	_	_	_	_
33-8	5111-5113	an	time[265]	giv[265]	_	_
33-9	5114-5122	immortal	time[265]	giv[265]	_	_
33-10	5123-5127	time	time[265]	giv[265]	_	_
33-11	5128-5130	of	time[265]	giv[265]	_	_
33-12	5131-5134	six	time[265]|time[266]	giv[265]|giv[266]	_	_
33-13	5135-5141	months	time[265]|time[266]	giv[265]|giv[266]	_	_
33-14	5142-5146	that	time[265]|time[266]	giv[265]|giv[266]	_	_
33-15	5147-5150	may	time[265]|time[266]	giv[265]|giv[266]	_	_
33-16	5151-5155	have	time[265]|time[266]	giv[265]|giv[266]	_	_
33-17	5156-5164	enriched	time[265]|time[266]	giv[265]|giv[266]	_	_
33-18	5165-5168	our	time[265]|time[266]|person|abstract[268]	giv[265]|giv[266]|giv|new[268]	_	_
33-19	5169-5175	series	time[265]|time[266]|abstract[268]	giv[265]|giv[266]|new[268]	_	_
33-20	5176-5178	of	time[265]|time[266]|abstract[268]	giv[265]|giv[266]|new[268]	_	_
33-21	5179-5180	a	time[265]|time[266]|abstract[268]|abstract[269]	giv[265]|giv[266]|new[268]|new[269]	_	_
33-22	5181-5187	higher	time[265]|time[266]|abstract[268]|abstract[269]	giv[265]|giv[266]|new[268]|new[269]	_	_
33-23	5188-5194	number	time[265]|time[266]|abstract[268]|abstract[269]	giv[265]|giv[266]|new[268]|new[269]	_	_
33-24	5195-5197	of	time[265]|time[266]|abstract[268]|abstract[269]	giv[265]|giv[266]|new[268]|new[269]	_	_
33-25	5198-5206	low-risk	time[265]|time[266]|abstract[268]|abstract[269]|organization[270]	giv[265]|giv[266]|new[268]|new[269]|giv[270]	_	_
33-26	5207-5210	ACC	time[265]|time[266]|abstract[268]|abstract[269]|organization[270]	giv[265]|giv[266]|new[268]|new[269]|giv[270]	_	_
33-27	5211-5219	compared	_	_	_	_
33-28	5220-5222	to	_	_	_	_
33-29	5223-5231	recently	abstract[271]	new[271]	_	_
33-30	5232-5241	published	abstract[271]	new[271]	_	_
33-31	5242-5248	series	abstract[271]	new[271]	_	_
33-32	5249-5250	.	_	_	_	_
